Published in Clin Endocrinol (Oxf) on February 01, 2011
Adrenal disorders in pregnancy. Nat Rev Endocrinol (2012) 0.81
Paraparesis secondary to hypokalaemia with hyporeninemic hypoaldosteronism during pregnancy: a diagnostic dilemma. Obstet Med (2013) 0.75
Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension (2006) 4.20
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol (2006) 3.74
Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet (2013) 2.83
Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension (2012) 2.31
LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab (2013) 2.30
Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens (2006) 2.09
Cellular mechanisms of insulin resistance in rats with fructose-induced hypertension. Am J Hypertens (2003) 1.88
Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol (2003) 1.79
Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension (2013) 1.76
Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J (2007) 1.72
Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults. J Am Soc Nephrol (2006) 1.63
Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab (2009) 1.53
KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension (2011) 1.51
Persistent psychological distress in patients treated for endocrine disease. Psychother Psychosom (2004) 1.51
The functional Q84R polymorphism of mammalian Tribbles homolog TRB3 is associated with insulin resistance and related cardiovascular risk in Caucasians from Italy. Diabetes (2005) 1.49
Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Hypertension (2009) 1.45
GILZ, a new target for the transcription factor FoxO3, protects T lymphocytes from interleukin-2 withdrawal-induced apoptosis. Blood (2004) 1.39
Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab (2008) 1.38
Left ventricular structural and functional characteristics in Cushing's syndrome. J Am Coll Cardiol (2003) 1.38
Expanding role of AMPK in endocrinology. Trends Endocrinol Metab (2006) 1.29
Characterization of rat NDRG2 (N-Myc downstream regulated gene 2), a novel early mineralocorticoid-specific induced gene. J Biol Chem (2002) 1.27
Aldosterone-producing adenoma formation in the adrenal cortex involves expression of stem/progenitor cell markers. Endocrinology (2011) 1.21
High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) (2004) 1.21
Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab (2005) 1.19
Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism. Hypertension (2010) 1.18
In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother (2008) 1.16
MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res (2009) 1.14
A common polymorphism in the mineralocorticoid receptor modulates stress responsiveness. J Clin Endocrinol Metab (2006) 1.13
Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension (2007) 1.13
Adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab (2012) 1.12
AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J (2008) 1.11
Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens (2007) 1.10
Cardiovascular risk in Cushing's syndrome. Pituitary (2004) 1.07
Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology (2010) 1.07
Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology (2010) 1.05
WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Hum Mol Genet (2013) 1.05
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol (2010) 1.04
Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab (2008) 1.03
Self image and quality of life in acromegaly. Pituitary (2002) 1.03
Brown adipocytes are novel sites of expression and regulation of adiponectin and resistin. FEBS Lett (2002) 1.03
Effect of glucocorticoids on adiponectin: a study in healthy subjects and in Cushing's syndrome. Eur J Endocrinol (2004) 1.00
Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. J Clin Endocrinol Metab (2008) 1.00
Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism. Hum Mutat (2007) 1.00
Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing's disease and pseudo-Cushing state: a comparative study. Clin Endocrinol (Oxf) (2011) 0.99
Coagulopathy in Cushing's syndrome. Neuroendocrinology (2010) 0.99
Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertil Steril (2008) 0.99
Insulin receptors and renal sodium handling in hypertensive fructose-fed rats. Kidney Int (2003) 0.98
The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism. Mol Cell Endocrinol (2011) 0.98
Development of overt Cushing's syndrome in patients with adrenal incidentaloma. Eur J Endocrinol (2002) 0.97
Distinctive modulation of inflammatory and metabolic parameters in relation to zinc nutritional status in adult overweight/obese subjects. J Nutr Biochem (2009) 0.97
Testosterone and cardiovascular risk. Intern Emerg Med (2013) 0.97
Adipose tissue as an endocrine organ? A review of recent data related to cardiovascular complications of endocrine dysfunctions. Clin Exp Hypertens (2004) 0.97
Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens (2007) 0.96
Role of nitric oxide concentrations on human sperm motility. J Androl (2004) 0.95
Activated V gamma 9V delta 2 T cells trigger granulocyte functions via MCP-2 release. J Immunol (2009) 0.95
Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab (2005) 0.94
Coenzyme Q(10) supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. Fertil Steril (2004) 0.94
The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways. Invest New Drugs (2014) 0.93
Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells. Eur J Immunol (2006) 0.92
Psychosocial impairment in patients treated for pituitary disease: a controlled study. Clin Endocrinol (Oxf) (2007) 0.91
Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. Eur J Endocrinol (2006) 0.90
Managing Cushing's disease: the state of the art. Endocrine (2014) 0.90
Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism. J Clin Endocrinol Metab (2003) 0.90
A functional variant of the adipocyte glycerol channel aquaporin 7 gene is associated with obesity and related metabolic abnormalities. Diabetes (2007) 0.90
Evaluation of circulating thyroid-specific transcripts as markers of thyroid cancer relapse. Int J Cancer (2004) 0.90
Cardiovascular effects of aldosterone: insight from adult carriers of mineralocorticoid receptor mutations. Circ Cardiovasc Genet (2013) 0.90
Harmful effects of functional hypercortisolism: a working hypothesis. Endocrine (2013) 0.90
The functional c.-2G>C variant of the mineralocorticoid receptor modulates blood pressure, renin, and aldosterone levels. Hypertension (2010) 0.90
Polymorphisms of EDNRB, ATG, and ACE genes in salt-sensitive hypertension. Can J Physiol Pharmacol (2008) 0.90
Vascular endothelial growth factor and microvessel density in periodontitis patients with and without diabetes. J Periodontol (2009) 0.89
KCNJ5 mutations in aldosterone producing adenoma and relationship with adrenal cortex remodeling. Mol Cell Endocrinol (2013) 0.89
Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord (2010) 0.88
In situ analysis of human menin in normal and neoplastic pancreatic tissues: evidence for differential expression in exocrine and endocrine cells. J Clin Endocrinol Metab (2003) 0.87
Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations. Pituitary (2015) 0.86
Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension (2003) 0.85
Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists. Curr Vasc Pharmacol (2012) 0.85
Primary aldosteronism, a major form of low renin hypertension: from screening to diagnosis. Trends Endocrinol Metab (2008) 0.85
Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing's syndrome. Eur J Endocrinol (2011) 0.85
Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1. J Am Soc Nephrol (2011) 0.85
Sexual symptoms in endocrine diseases: psychosomatic perspectives. Psychother Psychosom (2007) 0.85
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial. Pituitary (2015) 0.85